IL125839A0 - Uses of gdnf and gdnf receptor - Google Patents
Uses of gdnf and gdnf receptorInfo
- Publication number
- IL125839A0 IL125839A0 IL12583997A IL12583997A IL125839A0 IL 125839 A0 IL125839 A0 IL 125839A0 IL 12583997 A IL12583997 A IL 12583997A IL 12583997 A IL12583997 A IL 12583997A IL 125839 A0 IL125839 A0 IL 125839A0
- Authority
- IL
- Israel
- Prior art keywords
- gdnfrα
- gdnf
- methods
- receptor
- antibodies
- Prior art date
Links
- 102000004216 Glial cell line-derived neurotrophic factor receptors Human genes 0.000 title 1
- 108090000722 Glial cell line-derived neurotrophic factor receptors Proteins 0.000 title 1
- 101150082979 gdnf gene Proteins 0.000 title 1
- 102000024452 GDNF Human genes 0.000 abstract 2
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Silver Salt Photography Or Processing Solution Therefor (AREA)
- Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
- Photoreceptors In Electrophotography (AREA)
- Steroid Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Compounds Of Unknown Constitution (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61590296A | 1996-03-14 | 1996-03-14 | |
US61823696A | 1996-03-14 | 1996-03-14 | |
PCT/US1997/004363 WO1997033912A2 (en) | 1996-03-14 | 1997-03-13 | Uses of gdnf and gdnf receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
IL125839A0 true IL125839A0 (en) | 1999-04-11 |
Family
ID=27087630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL12583997A IL125839A0 (en) | 1996-03-14 | 1997-03-13 | Uses of gdnf and gdnf receptor |
Country Status (12)
Country | Link |
---|---|
US (4) | US6504007B1 (ja) |
EP (1) | EP0888385B1 (ja) |
JP (1) | JP4301347B2 (ja) |
AT (1) | ATE247667T1 (ja) |
AU (1) | AU719482B2 (ja) |
CA (1) | CA2246768C (ja) |
DE (1) | DE69724241T2 (ja) |
DK (1) | DK0888385T3 (ja) |
ES (1) | ES2206695T3 (ja) |
IL (1) | IL125839A0 (ja) |
PT (1) | PT888385E (ja) |
WO (1) | WO1997033912A2 (ja) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6696259B1 (en) * | 1995-11-13 | 2004-02-24 | Licentia Ltd. | Assays using glial cell line-derived neurotrophic factor receptors |
DE69724241T2 (de) | 1996-03-14 | 2004-06-09 | Genentech, Inc., South San Francisco | Gdnf-rezeptor und dessen verwendung |
BR9710665A (pt) * | 1996-05-08 | 1999-08-17 | Biogen Inc | Compostos que promovem o desenvolvimento do tecido |
US6677135B1 (en) | 1996-05-08 | 2004-01-13 | Biogen, Inc. | Ret ligand (RetL) for stimulating neutral and renal growth |
US20020068361A1 (en) * | 1997-04-08 | 2002-06-06 | Douglas Clary | Methods of evaluating specific cellular functions of receptor protein tyrosine kinases in a ligand independent manner |
WO1999049039A2 (en) * | 1998-03-23 | 1999-09-30 | Genentech, Inc. | GFRα3 AND ITS USES |
US7026138B1 (en) | 1998-03-23 | 2006-04-11 | Genentech, Inc. | Polynucleotides encoding GFRα3 |
DE19816186A1 (de) * | 1998-04-14 | 1999-10-21 | Univ Muenchen L Maximilians | GDNF-kodierende DNA, Teile davon und GDNF-Varianten |
US6620382B1 (en) | 1998-05-22 | 2003-09-16 | Biopheresis Technologies, Llc. | Method and compositions for treatment of cancers |
US8197430B1 (en) | 1998-05-22 | 2012-06-12 | Biopheresis Technologies, Inc. | Method and system to remove cytokine inhibitor in patients |
AU2354600A (en) * | 1998-12-09 | 2000-06-26 | Amgen, Inc. | Grnf4 a neurotrophic factor |
GB9915200D0 (en) | 1999-06-29 | 1999-09-01 | Janssen Pharmaceutica Nv | Neurotrophic factor receptor |
BRPI0406724A (pt) * | 2003-01-13 | 2005-12-20 | Macrogenics Inc | Proteìna de fusão dimérica, métodos de tratar, prevenir ou melhorar um ou mais sintomas de um distúrbio autoimune e um ou mais sintomas de púrpura trombocitopênica idiopática, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, método de produzir recombinantemente o polipeptìdeo, polipeptìdeo isolado, fragmento de qualquer um dos polipeptìdeos, e, molécula de ácido nucleico isolada |
US7480382B2 (en) * | 2003-09-30 | 2009-01-20 | Microsoft Corporation | Image file container |
EP1863530B1 (en) * | 2005-03-11 | 2010-07-14 | Oncotherapy Science, Inc. | Methods for damaging cells using effector functions of anti-gfra1 antibodies |
US8288354B2 (en) * | 2005-12-28 | 2012-10-16 | The Scripps Research Institute | Natural antisense and non-coding RNA transcripts as drug targets |
US7863295B2 (en) * | 2008-02-12 | 2011-01-04 | Children's Medical Center Corporation | Treatments for neuropathy |
JP6128732B2 (ja) * | 2008-10-03 | 2017-05-17 | クルナ・インコーポレーテッド | アポリポタンパク質−a1に対する天然アンチセンス転写物の抑制によるアポリポタンパク質−a1関連疾患の治療 |
KR101829469B1 (ko) * | 2008-12-04 | 2018-03-30 | 큐알엔에이, 인크. | Epo에 대한 천연 안티센스 전사체의 억제에 의해 에리트로포에틴(epo) 관련된 질환의 치료 |
KR101761424B1 (ko) * | 2008-12-04 | 2017-07-26 | 큐알엔에이, 인크. | Vegf에 대한 천연 안티센스 전사체의 억제에 의해 맥관 내피 성장 인자(vegf) 관련된 질환의 치료 |
WO2010065787A2 (en) | 2008-12-04 | 2010-06-10 | Curna, Inc. | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene |
CN102387817B (zh) | 2009-02-12 | 2018-01-30 | 库尔纳公司 | 通过抑制针对脑衍生神经营养因子(bdnf)的天然反义转录物来治疗bdnf相关的疾病 |
WO2010093906A2 (en) * | 2009-02-12 | 2010-08-19 | Curna, Inc. | Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf |
WO2010107733A2 (en) | 2009-03-16 | 2010-09-23 | Curna, Inc. | Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2 |
US9708604B2 (en) | 2009-03-17 | 2017-07-18 | Curna, Inc. | Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1 |
US9155754B2 (en) | 2009-05-06 | 2015-10-13 | Curna, Inc. | Treatment of ABCA1 gene related diseases by inhibition of a natural antisense transcript to ABCA1 |
US20120046236A1 (en) | 2009-05-06 | 2012-02-23 | Opko Curna Llc | Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp |
KR101742334B1 (ko) | 2009-05-08 | 2017-06-01 | 큐알엔에이, 인크. | Dmd 패밀리에 대한 천연 안티센스 전사체의 억제에 의한 디스트로핀 패밀리 관련된 질환의 치료 |
DK2432881T3 (en) | 2009-05-18 | 2018-02-26 | Curna Inc | TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR |
CA2762987A1 (en) | 2009-05-22 | 2010-11-25 | Joseph Collard | Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3 |
CN103221541B (zh) | 2009-05-28 | 2017-03-01 | 库尔纳公司 | 通过抑制抗病毒基因的天然反义转录物来治疗抗病毒基因相关疾病 |
WO2010148065A2 (en) | 2009-06-16 | 2010-12-23 | Curna, Inc. | Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1 |
CA2765700C (en) | 2009-06-16 | 2021-01-05 | Opko Curna, Llc | Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene |
EP2446036B1 (en) | 2009-06-24 | 2017-03-01 | CuRNA, Inc. | Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2 |
US8921330B2 (en) | 2009-06-26 | 2014-12-30 | Curna, Inc. | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
US20120252869A1 (en) | 2009-07-24 | 2012-10-04 | Opko Curna, Llc | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
JP6128848B2 (ja) | 2009-08-05 | 2017-05-17 | クルナ・インコーポレーテッド | インスリン遺伝子(ins)に対する天然アンチセンス転写物の抑制によるインスリン遺伝子(ins)関連疾患の治療 |
CN102625841A (zh) | 2009-08-11 | 2012-08-01 | 欧科库尔纳有限责任公司 | 通过抑制脂连蛋白(adipoq)的天然反义转录物治疗脂连蛋白(adipoq)相关疾病 |
CN102482670B (zh) | 2009-08-21 | 2018-06-15 | 库尔纳公司 | 通过抑制‘hsp70-相互作用蛋白的c末端’(chip)的天然反义转录物而治疗chip相关疾病 |
US9023822B2 (en) | 2009-08-25 | 2015-05-05 | Curna, Inc. | Treatment of 'IQ motif containing GTPase activating protein' (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP |
ES2664591T3 (es) | 2009-09-25 | 2018-04-20 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la filagrina (flg) mediante la modulación de la expresión y actividad del gen FLG |
DK2513310T3 (en) | 2009-12-16 | 2018-02-05 | Curna Inc | TREATMENT OF DISEASES CONNECTED WITH MEMBRANE-BONDED TRANSCRIPTION FACTOR Peptidase, site 1 (MBTPS1), BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTION TO MBTPS1 |
DK2516648T3 (en) | 2009-12-23 | 2018-02-12 | Curna Inc | TREATMENT OF HEPATOCYTE GROWTH FACTOR (HGF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT AGAINST HGF |
RU2619185C2 (ru) | 2009-12-23 | 2017-05-12 | Курна, Инк. | Лечение заболеваний, связанных с разобщающим белком 2 (ucp2), путем ингибирования природного антисмыслового транскрипта к ucp2 |
US8962585B2 (en) | 2009-12-29 | 2015-02-24 | Curna, Inc. | Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63 |
JP5993744B2 (ja) | 2009-12-29 | 2016-09-14 | カッパーアールエヌエー,インコーポレイテッド | 核呼吸因子1(nrf1)に対する天然アンチセンス転写物の阻害による核呼吸因子1関連疾患の治療 |
CN102791862B (zh) | 2009-12-31 | 2017-04-05 | 库尔纳公司 | 通过抑制胰岛素受体底物2(irs2)和转录因子e3(tfe3)的天然反义转录物而治疗irs2相关疾病 |
WO2011082409A2 (en) | 2010-01-04 | 2011-07-07 | Curna, Inc. | Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8 |
EP2521785B1 (en) | 2010-01-06 | 2022-03-09 | CuRNA, Inc. | Inhibition of natural antisense transcript to a pancreatic developmental gene for use in a treatment of pancreatic developmental gene related diseases |
ES2664866T3 (es) | 2010-01-11 | 2018-04-23 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la globulina fijadora de hormonas sexuales (shbg) mediante inhibición del transcrito antisentido natural a shbg |
RU2611192C2 (ru) | 2010-01-25 | 2017-02-21 | Курна, Инк. | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С РНКазой Н1, ПУТЕМ ИНГИБИРОВАНИЯ ПРИРОДНОГО АНТИСМЫСЛОВОГО ТРАНСКРИПТА К РНКазе Н1 |
JP5976548B2 (ja) | 2010-02-22 | 2016-08-23 | カッパーアールエヌエー,インコーポレイテッド | Pycr1に対する天然アンチセンス転写物の阻害によるピロリン−5−カルボン酸レダクターゼ1(pycr1)関連疾患の治療 |
ES2657969T3 (es) | 2010-04-02 | 2018-03-07 | Curna, Inc. | Tratamiento de enfermedades relacionadas con el Factor 3 estimulante de colonias (CSF3) por inhibición del transcrito antisentido natural a CSF3 |
US9044494B2 (en) | 2010-04-09 | 2015-06-02 | Curna, Inc. | Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21 |
KR101915115B1 (ko) | 2010-05-03 | 2018-11-05 | 큐알엔에이, 인크. | 시르투인 (sirt)에 대한 자연 안티센스 전사체의 저해에 의한 시르투인 (sirt) 관련된 질환의 치료 |
TWI586356B (zh) | 2010-05-14 | 2017-06-11 | 可娜公司 | 藉由抑制par4天然反股轉錄本治療par4相關疾病 |
ES2664572T3 (es) | 2010-05-26 | 2018-04-20 | Curna, Inc. | Tratamiento de enfermedades relacionadas con el homólogo atonal 1 (ATOH1) mediante inhibición del transcrito antisentido natural a ATOH1 |
EP2576784B1 (en) | 2010-05-26 | 2017-11-15 | CuRNA, Inc. | Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra |
CN103025873B (zh) | 2010-06-23 | 2018-05-08 | 库尔纳公司 | 通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病 |
CA2805318A1 (en) | 2010-07-14 | 2012-01-19 | Curna, Inc. | Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg |
WO2012047956A2 (en) | 2010-10-06 | 2012-04-12 | Opko Curna Llc | Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4 |
CN103180445B (zh) | 2010-10-22 | 2018-02-16 | 库尔纳公司 | 通过抑制α‑L‑艾杜糖醛酸酶(IDUA)的天然反义转录物而治疗IDUA相关疾病 |
WO2012068340A2 (en) | 2010-11-18 | 2012-05-24 | Opko Curna Llc | Antagonat compositions and methods of use |
CN103459599B (zh) | 2010-11-23 | 2017-06-16 | 库尔纳公司 | 通过抑制nanog的天然反义转录物而治疗nanog相关疾病 |
CA2838588C (en) | 2011-06-09 | 2021-09-14 | Curna, Inc. | Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn |
US11492383B2 (en) | 2011-06-24 | 2022-11-08 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
BR112014005234A2 (pt) | 2011-09-06 | 2017-04-11 | Curna Inc | tratamento de doenças relacionadas com subunididades alfa dos canais de sódio dependentes de voltagem (scnxa) com pequenas moléculas |
HUE040179T2 (hu) | 2012-03-15 | 2019-02-28 | Curna Inc | Agyi eredetû neutrotróf faktorral (Brain-derived neurotrophic factor, BDNF) összefüggõ betegségek kezelése a BDNF-fel kapcsolatos természetes antiszensz transzkriptumok gátlása révén |
EP3436078B1 (en) * | 2016-03-31 | 2021-10-27 | University of Cincinnati | Methods and compositions for the treatment of als |
US20230346847A1 (en) * | 2020-08-24 | 2023-11-02 | The Johns Hopkins University | Juvenile protective factors to arrest and reverse aging in the enteric nervous system |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
HU220795B1 (hu) * | 1991-09-20 | 2002-05-28 | Amgen Inc. | Gliasejtvonal-eredetű neurotróf faktorfehérjék, továbbá berendezések és gyógyászati készítmények idegsejtkárosodás megelőzésére és kezelésére |
AU6709794A (en) | 1993-04-21 | 1994-11-08 | Brigham And Women's Hospital | Erythropoietin muteins with enhanced activity |
ZA946122B (en) | 1993-08-17 | 1995-03-20 | Amgen Inc | Erythropoietin analogs |
EP0737252A1 (en) | 1993-11-10 | 1996-10-16 | Amgen Inc. | Gene therapy vector for the treatment of low or defective red blood cell production |
US5844092A (en) * | 1994-03-18 | 1998-12-01 | Genentech, Inc. | Human TRK receptors and neurotrophic factor inhibitors |
US5550050A (en) | 1994-04-15 | 1996-08-27 | Cytotherapeutics, Inc. | Method for implanting encapsulated cells in a host |
DE69724241T2 (de) | 1996-03-14 | 2004-06-09 | Genentech, Inc., South San Francisco | Gdnf-rezeptor und dessen verwendung |
AU2948697A (en) | 1996-04-18 | 1997-11-12 | Siemens Aktiengesellschaft | Power supply for a longitudinal stator drive |
US6635668B1 (en) | 1998-07-22 | 2003-10-21 | The University Of North Carolina At Chapel Hill | Imidazoline receptor binding compounds |
AR020848A1 (es) | 1998-10-23 | 2002-05-29 | Amgen Inc | Metodos y composiciones para la prevencion y el tratamiento de anemia |
-
1997
- 1997-03-13 DE DE69724241T patent/DE69724241T2/de not_active Expired - Lifetime
- 1997-03-13 PT PT97915160T patent/PT888385E/pt unknown
- 1997-03-13 IL IL12583997A patent/IL125839A0/xx active IP Right Grant
- 1997-03-13 AU AU22172/97A patent/AU719482B2/en not_active Expired
- 1997-03-13 CA CA2246768A patent/CA2246768C/en not_active Expired - Lifetime
- 1997-03-13 DK DK97915160T patent/DK0888385T3/da active
- 1997-03-13 WO PCT/US1997/004363 patent/WO1997033912A2/en active IP Right Grant
- 1997-03-13 ES ES97915160T patent/ES2206695T3/es not_active Expired - Lifetime
- 1997-03-13 AT AT97915160T patent/ATE247667T1/de active
- 1997-03-13 JP JP53291797A patent/JP4301347B2/ja not_active Expired - Lifetime
- 1997-03-13 EP EP97915160A patent/EP0888385B1/en not_active Expired - Lifetime
- 1997-03-13 US US08/860,370 patent/US6504007B1/en not_active Expired - Lifetime
-
2001
- 2001-11-02 US US10/033,350 patent/US7105484B2/en not_active Expired - Lifetime
-
2006
- 2006-01-20 US US11/336,555 patent/US7691606B2/en not_active Expired - Fee Related
-
2009
- 2009-11-16 US US12/619,513 patent/US20100313283A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP4301347B2 (ja) | 2009-07-22 |
EP0888385B1 (en) | 2003-08-20 |
DE69724241T2 (de) | 2004-06-09 |
US6504007B1 (en) | 2003-01-07 |
JP2000511402A (ja) | 2000-09-05 |
US7691606B2 (en) | 2010-04-06 |
US20060142196A1 (en) | 2006-06-29 |
AU719482B2 (en) | 2000-05-11 |
DK0888385T3 (da) | 2003-12-15 |
CA2246768C (en) | 2013-12-31 |
US20030022284A1 (en) | 2003-01-30 |
US20100313283A1 (en) | 2010-12-09 |
US7105484B2 (en) | 2006-09-12 |
PT888385E (pt) | 2004-01-30 |
ES2206695T3 (es) | 2004-05-16 |
WO1997033912A3 (en) | 1998-02-05 |
ATE247667T1 (de) | 2003-09-15 |
EP0888385A2 (en) | 1999-01-07 |
WO1997033912A2 (en) | 1997-09-18 |
AU2217297A (en) | 1997-10-01 |
DE69724241D1 (de) | 2003-09-25 |
CA2246768A1 (en) | 1997-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL125839A0 (en) | Uses of gdnf and gdnf receptor | |
MX9709324A (es) | Compuestos terapeuticos que comprenden anticuerpos anti receptores fc. | |
BR9510486A (pt) | Compostos moduladores de receptores de esteróide e métodos | |
BG101806A (en) | Indole derivatives as 5-ht receptor antagoniss | |
TW200607814A (en) | Cell surface receptor isoforms and methods of identifying and using the same | |
MX9602879A (es) | Moleculas mutantes de ctla4 y usos de las mismas. | |
WO1999000410A3 (en) | Human extracellular matrix proteins | |
EA200200647A1 (ru) | АГОНИСТЫ β2-АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА | |
TW200616632A (en) | Compounds modulating c-kit activity and uses therefor | |
EP1073465A4 (en) | T-CELL INHIBITING RECEPTOR COMPOSITIONS AND THEIR USE | |
IL130954A0 (en) | Neurturin receptor | |
GR3025698T3 (en) | NOVEL GABAa RECEPTOR SUBTYPES AND METHODS FOR SCREENING DRUG COMPOUNDS USING IMIDAZOQUINOXALINES AND PYRROLOPYRIMIDINES TO BIND TO GABAa RECEPTOR SUBTYPES. | |
WO1995007934A3 (en) | Il8 inhibitors | |
AU9363398A (en) | Hepatitis c receptor protein cd81 | |
BRPI0507987A (pt) | métodos e compostos moduladores receptor de glicocorticóide | |
TR199700956T1 (xx) | Indazolkarboksamidler. | |
EA199800867A1 (ru) | Соединения тетрагидробетакарболина | |
AU2001245209A1 (en) | Screening methods for bone morphogenetic mimetics | |
WO2003055908A3 (en) | Bag3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases | |
AUPN646795A0 (en) | Neuropeptide Y-Y5 receptor | |
WO1995016709A3 (en) | Anti-mullerian hormone receptor polypeptides and antibodies thereto | |
PT1196188E (pt) | Anticorpos monoclonais selectivos para o fcv e sua utilizacao para o tratamento de doencas associadas ao fcv | |
Meng | Involvement of the striatum and the striatial adenosine in acute ethanol-induced motor impairment in rats. | |
Patel | The contribution of nonprotein domains to the function of the voltage-dependent sodium channel. | |
WO2000042172A3 (en) | Human homologues of proteins regulated by circadian rhythms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed |